The safety of ezetimibe and simvastatin combination for the treatment of hypercholesterolemia

References

• Barkas F, Liberopoulos EN, Kostapanos MS, et al. Lipid target achievement among patients with very high and high cardiovascular risk in a lipid clinic. Angiology. 2015;66:346–353.
   PubMed Web of Science ®Google Scholar
• Rizos CV, Barkas F, Elisaf MS. Reaching low density lipoprotein cholesterol targets. Curr Med Res Opin. 2014;30:1967–1969.
   PubMed Web of Science ®Google Scholar
• Toth PP, Davidson MH. Simvastatin plus ezetimibe: combination therapy for the management of dyslipidaemia. Expert Opin Pharmacother. 2005;6:131–139.
   PubMed Web of Science ®Google Scholar
• Agouridis AP, Filippatos TD, Katsiki N. Current lipid-modifying agents. Expert Opin Pharmacother. 2015;16:1117–1118.
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Tobert JA. Simvastatin: a review. Expert Opin Pharmacother. 2004;5:2583–2596.
   PubMed Web of Science ®Google Scholar
• Mauro VF. Clinical pharmacokinetics and practical applications of simvastatin. Clin Pharmacokinet. 1993;24:195–202.
   PubMed Web of Science ®Google Scholar
• Vickers S, Duncan CA, Vyas KP, et al. In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. Drug Metab Dispos. 1990;18:476–483.
   PubMed Web of Science ®Google Scholar
• Vickers S, Duncan CA, Chen IW, et al. Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug. Drug Metab Dispos. 1990;18:138–145.
   PubMed Web of Science ®Google Scholar
• Desai CS, Martin SS, Blumenthal RS. Non-cardiovascular effects associated with statins. BMJ. 2014;349:g3743.
   PubMed Web of Science ®Google Scholar
• Davis HR, Veltri EP. Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia. J Atheroscler Thromb. 2007;14:99–108.
   PubMed Web of Science ®Google Scholar
• van Heek M, Farley C, Compton DS, et al. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol. 2000;129:1748–1754.
   PubMed Web of Science ®Google Scholar
• Jia L, Betters JL, Yu L. Niemann-pick C1-like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport. Annu Rev Physiol. 2011;73:239–259.
   PubMed Web of Science ®Google Scholar
• Kosoglou T, Statkevich P, Johnson-Levonas AO, et al. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44:467–494.
   PubMed Web of Science ®Google Scholar
• Migoya EM, Bergman A, Hreniuk D, et al. Bioequivalence of an ezetimibe/simvastatin combination tablet and coadministration of ezetimibe and simvastatin as separate tablets in healthy subjects. Int J Clin Pharmacol Ther. 2006;44:83–92.
   PubMed Web of Science ®Google Scholar
• Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the scandinavian simvastatin survival study (4S). Lancet. 1994;344:1383–1389.
   PubMed Web of Science ®Google Scholar
• Athyros VG, Kakafika AI, Tziomalos K, et al. Pleiotropic effects of statins–clinical evidence. Curr Pharm Des. 2009;15:479–489.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Mikhailidis DP. Statins and heart failure. Angiology. 2008;59:58S–61S.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Elisaf MS. Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia. Expert Opin Pharmacother. 2011;12:1945–1958.
   PubMed Web of Science ®Google Scholar
• Collins R, Armitage J, Parish S, et al. MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005–2016.
   PubMed Web of Science ®Google Scholar
• Mikhailidis DP, Sibbring GC, Ballantyne CM, et al. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin. 2007;23:2009–2026.
   PubMed Web of Science ®Google Scholar
• Morrone D, Weintraub WS, Toth PP, et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis. 2012;223:251–261.
   PubMed Web of Science ®Google Scholar
• Kalogirou M, Tsimihodimos V, Gazi I, et al. Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr Med Res Opin. 2007;23:1169–1176.
   PubMed Web of Science ®Google Scholar
• Tremblay AJ, Lamarche B, Hogue JC, et al. Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia. J Lipid Res. 2009;50:1463–1471.
   PubMed Web of Science ®Google Scholar
• Telford DE, Sutherland BG, Edwards JY, et al. The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin. J Lipid Res. 2007;48:699–708.
   PubMed Web of Science ®Google Scholar
• Roberts WC. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol. 1997;80:106–107.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Brandrup-Wognsen G, Palmer M, et al. Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol. 2010;105:69–76.
   PubMed Web of Science ®Google Scholar
• Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation. 2000;101:207–213.
   PubMed Web of Science ®Google Scholar
• Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002;40:2125–2134.
   PubMed Web of Science ®Google Scholar
• Ohbu-Murayama K, Adachi H, Hirai Y, et al. Ezetimibe combined with standard diet and exercise therapy improves insulin resistance and atherosclerotic markers in patients with metabolic syndrome. J Diabetes Investig. 2015;6:325–333.
   PubMed Web of Science ®Google Scholar
• Chang E, Kim L, Choi JM, et al. Ezetimibe stimulates intestinal glucagon-like peptide 1 secretion via the MEK/ERK pathway rather than dipeptidyl peptidase 4 inhibition. Metabolism. 2015;64:633–641.
   PubMed Web of Science ®Google Scholar
• Kalogirou M, Tsimihodimos V, Elisaf M. Pleiotropic effects of ezetimibe: do they really exist? Eur J Pharmacol. 2010;633:62–70.
   PubMed Web of Science ®Google Scholar
• Nakou ES, Filippatos TD, Kiortsis DN, et al. The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia. Expert Opin Pharmacother. 2008;9:3151–3158.
   PubMed Web of Science ®Google Scholar
• Nakou ES, Filippatos TD, Agouridis AP, et al. The effects of ezetimibe and/or orlistat on triglyceride-rich lipoprotein metabolism in obese hypercholesterolemic patients. Lipids. 2010;45:445–450.
   PubMed Web of Science ®Google Scholar
• Nakou ES, Filippatos TD, Georgoula M, et al. The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. Curr Med Res Opin. 2008;24:1919–1929.
   PubMed Web of Science ®Google Scholar
• Takeshita Y, Takamura T, Honda M, et al. The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial. Diabetologia. 2014;57:878–890.
   PubMed Web of Science ®Google Scholar
• Derdemezis C, Filippatos T, Tselepis A, et al. Effects of ezetimibe, either alone or in combination with atorvastatin, on serum visfatin levels: a pilot study. Expert Opin Pharmacother. 2008;9:1829–1837.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Elisaf MS. Statin-ezetimibe combination therapy in diabetic individuals. Angiology. 2015. doi:10.1177/0003319715598887. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Elisaf MS. Effects of ezetimibe/simvastatin combination on metabolic parameters. Int J Cardiol. 2016;202:273–274.
   PubMed Web of Science ®Google Scholar
• Florentin M, Liberopoulos EN, Moutzouri E, et al. The effect of simvastatin alone versus simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemia. Curr Med Res Opin. 2011;27:685–692.
   PubMed Web of Science ®Google Scholar
• Kostapanos MS, Elisaf MS, Mikhailidis DP. Effect of atorvastatin monotherapy and low-dose atorvastatin/ezetimibe combination on fasting and postprandial triglycerides in combined hyperlipidemia. J Cardiovasc Pharmacol Ther. 2012;17:427.
   PubMed Web of Science ®Google Scholar
• Moutzouri E, Liberopoulos EN, Florentin M, et al. Effects of statin monotherapy versus statin plus ezetimibe combination on serum uric acid levels. J Cardiovasc Pharmacol Ther. 2013;18:13–18.
   PubMed Web of Science ®Google Scholar
• Moutzouri E, Liberopoulos EN, Tellis CC, et al. Comparison of the effect of simvastatin versus simvastatin/ezetimibe versus rosuvastatin on markers of inflammation and oxidative stress in subjects with hypercholesterolemia. Atherosclerosis. 2013;231:8–14.
   PubMed Web of Science ®Google Scholar
• Moutzouri E, Tellis CC, Rousouli K, et al. Effect of simvastatin or its combination with ezetimibe on toll-like receptor expression and lipopolysaccharide - induced cytokine production in monocytes of hypercholesterolemic patients. Atherosclerosis. 2012;225:381–387.
   PubMed Web of Science ®Google Scholar
• Agouridis AP, Filippatos TD, Tsimihodimos V, et al. Combinations of ezetimibe with nonstatin drug regimens affecting lipid metabolism. Expert Rev Cardiovasc Ther. 2011;9:355–366.
   PubMedGoogle Scholar
• Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181–2192.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Blazing MA, Braunwald E, Ezetimibe plus a statin after acute coronary syndromes. N Engl J Med. 2015;373:1476–1477.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Elisaf MS. Are lower levels of LDL-cholesterol really better? Looking at the results of IMPROVE-IT: opinions of three experts - III. Hellenic J Cardiol. 2015;56:7–9.
   PubMed Web of Science ®Google Scholar
• [cited 2016 Feb 9]. Available from: https://www.escardio.org/The-ESC/Press-Office/Press-releases/Last-5-years/ezetimibe-reduces-cardiovascular-events-in-diabetics-with-recent-acute-coronary-syndrome
   Google Scholar
• European Society Congress 2015 press releases [Internet]. 2015 [cited 2016 Feb 10]. Available from: http://www.medpagetoday.com/Cardiology/CardioBrief/55256
   Google Scholar
• Food and Drug Administration [Internet]. [cited 2016 Feb 9]. Available from: http://www.fda.gov/safety/medwatch/safetyinformation/ucm208609.htm
   Google Scholar
• Ip CK, Jin DM, Gao JJ, et al. Effects of add-on lipid-modifying therapy on top of background statin treatment on major cardiovascular events: a meta-analysis of randomized controlled trials. Int J Cardiol. 2015;191:138–148.
   PubMed Web of Science ®Google Scholar
• Fernandez G, Spatz ES, Jablecki C, et al. Statin myopathy: a common dilemma not reflected in clinical trials. Cleve Clin J Med. 2011;78:393–403.
   PubMedGoogle Scholar
• Filippatos TD, Elisaf MS. Safety considerations with fenofibrate/simvastatin combination. Expert Opin Drug Saf. 2015;14:1481–1493.
   PubMed Web of Science ®Google Scholar
• Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003;289:1681–1690.
   PubMed Web of Science ®Google Scholar
• Agouridis AP, Nair DR, Mikhailidis DP. Strategies to overcome statin intolerance. Expert Opin Drug Metab Toxicol. 2015;11:851–855.
   PubMed Web of Science ®Google Scholar
• Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy-European atherosclerosis society consensus panel statement on assessment, aetiology and management. Eur Heart J. 2015;36:1012–1022.
   PubMed Web of Science ®Google Scholar
• Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681.
   PubMed Web of Science ®Google Scholar
• Armitage J, Bowman L, Wallendszus K, et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet. 2010;376:1658–1669.
   PubMed Web of Science ®Google Scholar
• FDA drug safety communication: new restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. [cited 2016 Feb 10]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm256581.htm
   Google Scholar
• Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011;63:157–181.
   PubMed Web of Science ®Google Scholar
• Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009;158:693–705.
   PubMed Web of Science ®Google Scholar
• Davidson MH, Maccubbin D, Stepanavage M, et al. Striated muscle safety of ezetimibe/simvastatin (Vytorin). Am J Cardiol. 2006;97:223–228.
   PubMed Web of Science ®Google Scholar
• de Denus S, Spinler SA, Miller K, et al. Statins and liver toxicity: a meta-analysis. Pharmacotherapy. 2004;24:584–591.
   PubMed Web of Science ®Google Scholar
• Stone NJ, Robinson JG, Lichtenstein AH, et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2013;2014(63):2889–2934.
   Google Scholar
• Liu Q, Tobias H, Petrovic LM. Drug-induced liver injury associated with ezetimibe therapy. Dig Dis Sci. 2007;52:602–605.
   PubMed Web of Science ®Google Scholar
• Stolk MF, Becx MC, Kuypers KC, et al. Severe hepatic side effects of ezetimibe. Clin Gastroenterol Hepatol. 2006;4:908–911.
   PubMed Web of Science ®Google Scholar
• Mombellia G, Calabresib L, Sirtoria C. Asymptomatic EBV infection may uncover ezetimibe liver alterations in a hypercholesterolemic child. J Med Cases. 2013;4:66–68.
   Google Scholar
• Ballantyne CM, Abate N, Yuan Z, et al. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the vytorin versus atorvastatin (VYVA) study. Am Heart J. 2005;149:464–473.
   PubMed Web of Science ®Google Scholar
• McKenney JM, Jones PH, Bays HE, et al. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis. 2007;192:432–437.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142:1592–1609.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Elisaf MS. Role of ezetimibe in non-alcoholic fatty liver disease. World J Hepatol. 2011;3:265–267.
   PubMedGoogle Scholar
• Filippatos TD, Elisaf MS. Combination drug treatment in patients with non-alcoholic fatty liver disease. World J Hepatol. 2010;2:139–142.
   PubMedGoogle Scholar
• Averna M. The effect of ezetimibe on NAFLD. Atheroscler Suppl. 2015;17:27–34.
   PubMed Web of Science ®Google Scholar
• Nelson A, Torres DM, Morgan AE, et al. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial. J Clin Gastroenterol. 2009;43:990–994.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
   PubMed Web of Science ®Google Scholar
• Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735–742.
   PubMed Web of Science ®Google Scholar
• Koh KK, Quon MJ, Han SH, et al. Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. Atherosclerosis. 2009;204:483–490.
   PubMed Web of Science ®Google Scholar
• Navarese EP, Szczesniak A, Kolodziejczak M, et al. Statins and risk of new-onset diabetes mellitus: is there a rationale for individualized statin therapy? Am J Cardiovasc Drugs. 2014;14:79–87.
   PubMed Web of Science ®Google Scholar
• Yada T, Nakata M, Shiraishi T, et al. Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells. Br J Pharmacol. 1999;126:1205–1213.
   PubMed Web of Science ®Google Scholar
• Nakata M, Nagasaka S, Kusaka I, et al. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia. 2006;49:1881–1892.
   PubMed Web of Science ®Google Scholar
• Koh KK, Quon MJ, Han SH, et al. Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. Diabetes Care. 2008;31:776–782.
   PubMed Web of Science ®Google Scholar
• Navarese EP, Buffon A, Andreotti F, et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol. 2013;111:1123–1130.
   PubMed Web of Science ®Google Scholar
• Kohli P, Waters DD, Nemr R, et al. Risk of new-onset diabetes and cardiovascular risk reduction from high-dose statin therapy in pre-diabetics and non-pre-diabetics: an analysis from TNT and IDEAL. J Am Coll Cardiol. 2015;65:402–404.
   PubMed Web of Science ®Google Scholar
• Swerdlow DI, Preiss D, Kuchenbaecker KB, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet. 2015;385:351–361.
   PubMed Web of Science ®Google Scholar
• Agouridis AP, Kostapanos MS, Elisaf MS. Statins and their increased risk of inducing diabetes. Expert Opin Drug Saf. 2015;14:1835–1844.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Pradhan A, MacFadyen JG, et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380:565–571.
   PubMed Web of Science ®Google Scholar
• Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305:2556–2564.
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists Collaborators, Mihaylova B, Emberson J, et al.. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581–590.
   PubMed Web of Science ®Google Scholar
• Moutzouri E, Liberopoulos E, Mikhailidis DP, et al. Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance. Int J Clin Pract. 2011;65:1141–1148.
   PubMed Web of Science ®Google Scholar
• Barkas F, Elisaf M, Liberopoulos E, et al. Statin therapy with or without ezetimibe and the progression to diabetes. J Clin Lipidology. doi:10.1016/j.jacl.2015.11.015. [Epub ahead of print]
   Web of Science ®Google Scholar
• Koh KK, Oh PC, Sakuma I, et al. Vascular and metabolic effects of ezetimibe combined with simvastatin in patients with hypercholesterolemia. Int J Cardiol. 2015;199:126–131.
   PubMed Web of Science ®Google Scholar
• Kater AL, Batista MC, Ferreira SR. Improved endothelial function with simvastatin but unchanged insulin sensitivity with simvastatin or ezetimibe. Metabolism. 2010;59:921–926.
   PubMed Web of Science ®Google Scholar
• Blazing M. Incidence of new-onset diabetes in the IMPROVE-IT trial: does adding ezetimibe to simvastatin increase risk compared to simvastatin alone? Presented at: European Society of Cardiology Congress; 2015 Sep 1; London, England. Available from: https://www.acc.org/latest-in-cardiology/articles/2015/11/20/14/20/incidence-of-new-onset-diabetes-in-the-improve-it-trial?w_nav=Tab
   Google Scholar
• Qamar A, Alexander KM. [cited 2016 Feb 9]. Available from: http://www.acc.org/latest-in-cardiology/articles/2015/11/20/14/20/incidence-of-new-onset-diabetes-in-the-improve-it-trial
   Google Scholar
• Pattis P, Wiedermann CJ. Ezetimibe-associated immune thrombocytopenia. Ann Pharmacother. 2008;42:430–433.
   PubMed Web of Science ®Google Scholar
• Almquist T, Jacobson SH, Lins PE, et al. Effects of lipid-lowering treatment on platelet reactivity and platelet-leukocyte aggregation in diabetic patients without and with chronic kidney disease: a randomized trial. Nephrol Dial Transplant. 2012;27:3540–3546.
   PubMed Web of Science ®Google Scholar
• Haynes R, Lewis D, Emberson J, et al. Effects of lowering LDL cholesterol on progression of kidney disease. J Am Soc Nephrol. 2014;25:1825–1833.
   PubMed Web of Science ®Google Scholar
• Kiortsis DN, Filippatos TD, Mikhailidis DP, et al. Statin-associated adverse effects beyond muscle and liver toxicity. Atherosclerosis. 2007;195:7–16.
   PubMed Web of Science ®Google Scholar
• Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ. 2010;340:c2197.
   PubMed Web of Science ®Google Scholar
• Klein BE, Klein R, Lee KE, et al. Statin use and incident nuclear cataract. JAMA. 2006;295:2752–2758.
   PubMed Web of Science ®Google Scholar
• Erie JC, Pueringer MR, Brue SM, et al. Statin use and incident cataract surgery: a case-control study. Ophthalmic Epidemiol. 2016;23:40–45.
   PubMed Web of Science ®Google Scholar
• Wise SJ, Nathoo NA, Etminan M, et al. Statin use and risk for cataract: a nested case-control study of 2 populations in Canada and the United States. Can J Cardiol. 2014;30:1613–1619.
   PubMed Web of Science ®Google Scholar
• Leuschen J, Mortensen EM, Frei CR, et al. Association of statin use with cataracts: a propensity score-matched analysis. JAMA Ophthalmol. 2013;131:1427–1434.
   PubMed Web of Science ®Google Scholar
• Spence JD. Statins and cataracts: reverse causality? Can J Cardiol. 2015;31:691 e11.
   PubMed Web of Science ®Google Scholar
• Harris ML, Bron AJ, Brown NA, et al. Absence of effect of simvastatin on the progression of lens opacities in a randomised placebo controlled study. Oxford cholesterol study group. Br J Ophthalmol. 1995;79:996–1002.
   PubMed Web of Science ®Google Scholar
• Kostis JB, Dobrzynski JM. Prevention of cataracts by statins: a meta-analysis. J Cardiovasc Pharmacol Ther. 2014;19:191–200.
   PubMed Web of Science ®Google Scholar
• Bang CN, Greve AM, La Cour M, et al. Effect of randomized lipid lowering with simvastatin and ezetimibe on cataract development (from the Simvastatin and Ezetimibe in Aortic Stenosis Study). Am J Cardiol. 2015;116:1840–1844.
   PubMed Web of Science ®Google Scholar
• Adams AE, Bobrove AM, Gilliam AC. Statins and “chameleon-like” cutaneous eruptions: simvastatin-induced acral cutaneous vesiculobullous and pustular eruption in a 70-year-old man. J Cutan Med Surg. 2010;14:207–211.
   PubMed Web of Science ®Google Scholar
• Peramiquel L, Serra E, Dalmau J, et al. Occupational contact dermatitis from simvastatin. Contact Dermatitis. 2005;52:286–287.
   PubMed Web of Science ®Google Scholar
• Oskay T, Kutluay L. Acute generalized exanthematous pustulosis induced by simvastatin. Clin Exp Dermatol. 2003;28:558–559.
   PubMed Web of Science ®Google Scholar
• Granados MT, de la Torre C, Cruces MJ, et al. Chronic actinic dermatitis due to simvastatin. Contact Dermatitis. 1998;38:294–295.
   PubMed Web of Science ®Google Scholar
• Morimoto K, Kawada A, Hiruma M, et al. Photosensitivity to simvastatin with an unusual response to photopatch and photo tests. Contact Dermatitis. 1995;33:274.
   PubMed Web of Science ®Google Scholar
• Roger D, Rolle F, Labrousse F, et al. Simvastatin-induced lichenoid drug eruption. Clin Exp Dermatol. 1994;19:88–89.
   PubMed Web of Science ®Google Scholar
• Ruger RD, Simon JC, Treudler R. Subacute-cutaneous lupus erythematosus induced by simvastatin. J Dtsch Dermatol Ges. 2011;9:54–55.
   PubMed Web of Science ®Google Scholar
• Bellini V, Assalve D, Lisi P. Urticarial vasculitis from simvastatin: what is the alternative drug? Dermatitis. 2010;21:223–224.
   PubMed Web of Science ®Google Scholar
• Fauchais AL, J IB, Maurage P, et al. [Polymyositis induced or associated with lipid-lowering drugs: five cases]. Rev Med Interne. 2004;25:294–298.
   PubMed Web of Science ®Google Scholar
• De Groot RE, Willems LN, Dijkman JH. Interstitial lung disease with pleural effusion caused by simvastin. J Intern Med. 1996;239:361–363.
   PubMed Web of Science ®Google Scholar
• Lantuejoul S, Brambilla E, Brambilla C, et al. Statin-induced fibrotic nonspecific interstitial pneumonia. Eur Respir J. 2002;19:577–580.
   PubMed Web of Science ®Google Scholar
• Keech AC, Armitage JM, Wallendszus KR, et al. Absence of effects of prolonged simvastatin therapy on nocturnal sleep in a large randomized placebo-controlled study. Oxford cholesterol study group. Br J Clin Pharmacol. 1996;42:483–490.
   PubMed Web of Science ®Google Scholar
• Eckernas SA, Roos BE, Kvidal P, et al. The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: a comparison of two structurally different HMG CoA reductase inhibitors in patients with primary moderate hypercholesterolaemia. Br J Clin Pharmacol. 1993;35:284–289.
   PubMed Web of Science ®Google Scholar
• Law MR, Thompson SG, Wald NJ. Assessing possible hazards of reducing serum cholesterol. BMJ. 1994;308:373–379.
   PubMed Web of Science ®Google Scholar
• Davison KM, Kaplan BJ. Lipophilic statin use and suicidal ideation in a sample of adults with mood disorders. Crisis. 2014;35:278–282.
   PubMedGoogle Scholar
• Haukka J, Niskanen L, Partonen T, et al. Statin usage and all-cause and disease-specific mortality in a nationwide study. Pharmacoepidemiol Drug Saf. 2012;21:61–69.
   PubMed Web of Science ®Google Scholar
• Callreus T, Agerskov Andersen U, Hallas J, et al. Cardiovascular drugs and the risk of suicide: a nested case-control study. Eur J Clin Pharmacol. 2007;63:591–596.
   PubMed Web of Science ®Google Scholar
• Yang CC, Jick SS, Jick H. Lipid-lowering drugs and the risk of depression and suicidal behavior. Arch Intern Med. 2003;163:1926–1932.
   PubMed Web of Science ®Google Scholar
• Huffman JC, Stern TA. Neuropsychiatric consequences of cardiovascular medications. Dialogues Clin Neurosci. 2007;9:29–45.
   PubMedGoogle Scholar
• Lv HL, Jin DM, Liu M, et al. Long-term efficacy and safety of statin treatment beyond six years: a meta-analysis of randomized controlled trials with extended follow-up. Pharmacol Res. 2014;81:64–73.
   PubMed Web of Science ®Google Scholar
• Rossebo AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343–1356.
   PubMed Web of Science ®Google Scholar
• Green A, Ramey DR, Emneus M, et al. Incidence of cancer and mortality in patients from the simvastatin and ezetimibe in aortic stenosis (SEAS) trial. Am J Cardiol. 2014;114:1518–1522.
   PubMed Web of Science ®Google Scholar
• Peto R, Emberson J, Landray M, et al. Analyses of cancer data from three ezetimibe trials. N Engl J Med. 2008;359:1357–1366.
   PubMed Web of Science ®Google Scholar
• Luo L, Yuan X, Huang W, et al. Safety of coadministration of ezetimibe and statins in patients with hypercholesterolaemia: a meta-analysis. Intern Med J. 2015;45:546–557.
   PubMed Web of Science ®Google Scholar
• Florentin M, Elisaf MS. Simvastatin interactions with other drugs. Expert Opin Drug Saf. 2012;11:439–444.
   PubMed Web of Science ®Google Scholar
• Watkins JL, Atkinson BJ, Pagliaro LC. Rhabdomyolysis in a prostate cancer patient taking ketoconazole and simvastatin: case report and review of the literature. Ann Pharmacother. 2011;45:e9.
   Google Scholar
• Molden E, Skovlund E, Braathen P. Risk management of simvastatin or atorvastatin interactions with CYP3A4 inhibitors. Drug Saf. 2008;31:587–596.
   PubMed Web of Science ®Google Scholar
• Itakura H, Vaughn D, Haller DG, et al. Rhabdomyolysis from cytochrome p-450 interaction of ketoconazole and simvastatin in prostate cancer. J Urol. 2003;169:613.
   PubMed Web of Science ®Google Scholar
• McKelvie PA, Dennett X. Myopathy associated with HMG-CoA reductase inhibitors (statins): a series of 10 patients and review of the literature. J Clin Neuromuscul Dis. 2002;3:143–148.
   PubMedGoogle Scholar
• Gilad R, Lampl Y. Rhabdomyolysis induced by simvastatin and ketoconazole treatment. Clin Neuropharmacol. 1999;22:295–297.
   PubMed Web of Science ®Google Scholar
• Roques S, Lytrivi M, Rusu D, et al. Rhabdomyolysis-induced acute renal failure due to itraconazole and simvastatin association. Drug Metabol Drug Interact. 2011;26:79–80.
   PubMedGoogle Scholar
• Saliba WR, Elias M. Severe myopathy induced by the co-administration of simvastatin and itraconazole. Eur J Intern Med. 2005;16:305.
   PubMedGoogle Scholar
• Krishna G, Ma L, Prasad P, et al. Effect of posaconazole on the pharmacokinetics of simvastatin and midazolam in healthy volunteers. Expert Opin Drug Metab Toxicol. 2012;8:1–10.
   PubMed Web of Science ®Google Scholar
• Page SR, Yee KC. Rhabdomyolysis in association with simvastatin and dosage increment in clarithromycin. Intern Med J. 2014;44:690–693.
   PubMed Web of Science ®Google Scholar
• Wagner J, Suessmair C, Pfister HW. Rhabdomyolysis caused by co-medication with simvastatin and clarithromycin. J Neurol. 2009;256:1182–1183.
   PubMed Web of Science ®Google Scholar
• Molden E, Andersson KS. Simvastatin-associated rhabdomyolysis after coadministration of macrolide antibiotics in two patients. Pharmacotherapy. 2007;27:603–607.
   PubMed Web of Science ®Google Scholar
• Fallah A, Deep M, Smallwood D, et al. Life-threatening rhabdomyolysis following the interaction of two commonly prescribed medications. Australas Med J. 2013;6:112–114.
   PubMedGoogle Scholar
• Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther. 1998;64:177–182.
   PubMed Web of Science ®Google Scholar
• Chauvin B, Drouot S, Barrail-Tran A, et al. Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. Clin Pharmacokinet. 2013;52:815–831.
   PubMed Web of Science ®Google Scholar
• Karnik NS, Maldonado JR. Antidepressant and statin interactions: a review and case report of simvastatin and nefazodone-induced rhabdomyolysis and transaminitis. Psychosomatics. 2005;46:565–568.
   PubMed Web of Science ®Google Scholar
• Scarfia RV, Clementi A, Granata A. Rhabdomyolysis and acute kidney injury secondary to interaction between simvastatin and cyclosporine. Ren Fail. 2013;35:1056–1057.
   PubMed Web of Science ®Google Scholar
• Yang WH, Zeng ZS, Ren XW, et al. Simvastatin-induced myopathy with concomitant use of cyclosporine: case report. Int J Clin Pharmacol Ther. 2011;49:772–777.
   PubMed Web of Science ®Google Scholar
• Tong J, Laport G, Lowsky R. Rhabdomyolysis after concomitant use of cyclosporine and simvastatin in a patient transplanted for multiple myeloma. Bone Marrow Transplant. 2005;36:739–740.
   PubMed Web of Science ®Google Scholar
• Hsu WC, Chen WH, Chang MT, et al. Colchicine-induced acute myopathy in a patient with concomitant use of simvastatin. Clin Neuropharmacol. 2002;25:266–268.
   PubMed Web of Science ®Google Scholar
• Herring R, Caldwell G, Wade S. Rhabdomyolysis caused by an interaction of simvastatin and fusidic acid. BMJ Case Rep. 2009;2009:pii: bcr03.2009.1722. doi:10.1136/bcr.03.2009.1722.
   Google Scholar
• Yuen SL, McGarity B. Rhabdomyolysis secondary to interaction of fusidic acid and simvastatin. Med J Aust. 2003;179:172.
   PubMed Web of Science ®Google Scholar
• Oh DH, Chan SQ, Wilson AM. Myopathy and possible intestinal dysfunction in a patient treated with colchicine and simvastatin. Med J Aust. 2012;197:332–333.
   PubMed Web of Science ®Google Scholar
• Justiniano M, Dold S, Espinoza LR. Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine. J Clin Rheumatol. 2007;13:266–268.
   PubMed Web of Science ®Google Scholar
• Lilja JJ, Neuvonen M, Neuvonen PJ. Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. Br J Clin Pharmacol. 2004;58:56–60.
   PubMed Web of Science ®Google Scholar
• Kyrklund C, Backman JT, Kivisto KT, et al. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther. 2000;68:592–597.
   PubMed Web of Science ®Google Scholar
• FDA drug safety communication. 2011 [cited 2015 Mar 30]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm256581.htm
   Google Scholar
• Ezetrol® (ezetimibe) package insert. [cited 2015 Dec 27]. Available from: http://www.old.health.gov.il/units/pharmacy/trufot/alonim/1149.PDF
   Google Scholar
• Robinson JG, Davidson MH. Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction. Expert Rev Cardiovasc Ther. 2006;4:461–476.
   PubMedGoogle Scholar